VYNE Therapeutics (VYNE) Insider Trading & Ownership $2.76 +0.09 (+3.37%) As of 01/24/2025 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VYNE Therapeutics (NASDAQ:VYNE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.80%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$43,800.00Number OfInsiders Selling(Last 12 Months)0 Get VYNE Insider Trade Alerts Want to know when executives and insiders are buying or selling VYNE Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address VYNE Insider Buying and Selling by Quarter VYNE Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/15/2025Patrick G LeporeDirectorBuy15,000$2.92$43,800.00 (Data available from 1/1/2013 forward) VYNE Insider Trading Activity - Frequently Asked Questions Who is on VYNE Therapeutics's Insider Roster? The list of insiders at VYNE Therapeutics includes Mutya Harsch, and Patrick G Lepore. Learn more on insiders at VYNE. What percentage of VYNE Therapeutics stock is owned by insiders? 4.80% of VYNE Therapeutics stock is owned by insiders. Learn more on VYNE's insider holdings. Which VYNE Therapeutics insiders have been buying company stock? The following insiders have purchased VYNE shares in the last 24 months: Mutya Harsch ($25,000.00), and Patrick G Lepore ($144,230.00). How much insider buying is happening at VYNE Therapeutics? Insiders have purchased a total of 58,000 VYNE shares in the last 24 months for a total of $169,230.00 bought. VYNE Therapeutics Key ExecutivesMr. David T. Domzalski (Age 57)CEO, President & Director Compensation: $1.61MDr. Iain A. Stuart Ph.D. (Age 51)Chief Scientific Officer Compensation: $856.82kMs. Mutya Harsch J.D. (Age 49)General Counsel, Chief Legal Officer & Company Secretary Compensation: $817.97kMr. Tyler Zeronda (Age 37)CFO & Treasurer Dr. Darrell S. Rigel FAAD (Age 73)M.D., Consultant Compensation: $40.2k More Insider Trading Tools from MarketBeat Related Companies ARTV Insider Trading NLTX Insider Trading CKPT Insider Trading CDTX Insider Trading MNPR Insider Trading FTLF Insider Trading ADAP Insider Trading PBYI Insider Trading CRBP Insider Trading FATE Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Small-Cap Stocks Insiders and Institutions Are Buying3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys This page (NASDAQ:VYNE) was last updated on 1/25/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
